Wedbush Maintains Outperform on Denali Therapeutics, Lowers Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico has maintained an Outperform rating on Denali Therapeutics (NASDAQ:DNLI) but has lowered the price target from $31 to $30.

May 08, 2024 | 2:20 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Wedbush maintains an Outperform rating on Denali Therapeutics but lowers the price target from $31 to $30.
The adjustment in price target by a reputable analyst like Laura Chico could have a mixed impact on DNLI's stock price. While maintaining an Outperform rating indicates a positive outlook on the company, the reduction in the price target might signal a tempered expectation for the stock's short-term growth potential. Investors might view this as a slight negative, but the continued positive rating suggests underlying confidence in the company's fundamentals.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100